SI-BONE (NASDAQ:SIBN) Posts Quarterly Earnings Results

Share on StockTwits

SI-BONE (NASDAQ:SIBN) issued its quarterly earnings results on Sunday. The company reported ($0.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.03, MarketWatch Earnings reports. SI-BONE had a negative net margin of 61.67% and a negative return on equity of 45.03%.

Shares of NASDAQ SIBN traded down $2.82 during trading hours on Tuesday, hitting $33.14. The stock had a trading volume of 13,727 shares, compared to its average volume of 287,842. The firm’s 50-day moving average price is $33.10 and its two-hundred day moving average price is $28.78. SI-BONE has a 52 week low of $14.37 and a 52 week high of $36.78. The company has a market capitalization of $1.09 billion, a P/E ratio of -21.00 and a beta of 1.41. The company has a debt-to-equity ratio of 0.39, a quick ratio of 12.22 and a current ratio of 12.65.

SIBN has been the topic of several recent analyst reports. Truist boosted their target price on shares of SI-BONE from $35.00 to $43.00 in a research note on Tuesday. Needham & Company LLC upped their price target on SI-BONE from $34.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday. Zacks Investment Research lowered SI-BONE from a “hold” rating to a “sell” rating in a research report on Friday, March 12th. Canaccord Genuity upped their target price on SI-BONE from $39.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Morgan Stanley raised their price target on shares of SI-BONE from $38.00 to $41.00 and gave the stock an “overweight” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. SI-BONE presently has an average rating of “Buy” and an average target price of $35.71.

In other news, CEO Jeffrey W. Dunn sold 2,112 shares of SI-BONE stock in a transaction that occurred on Friday, April 16th. The shares were sold at an average price of $33.65, for a total value of $71,068.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John Gordon Freund sold 235,887 shares of the business’s stock in a transaction on Monday, March 15th. The stock was sold at an average price of $31.13, for a total transaction of $7,343,162.31. The disclosure for this sale can be found here. Insiders sold 1,067,472 shares of company stock worth $32,658,438 in the last 90 days. 15.50% of the stock is currently owned by corporate insiders.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.

Further Reading: Dual Listing What You Need to Know

Earnings History for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with's FREE daily email newsletter.